A Study of HMPL-306 is testing a new medicine for blood cancers called hematological malignancies with a specific gene change, called mIDH. This is a phase 1 trial, meaning it's one of the first times this medicine is being tested in people. The study aims to see if the medicine is safe and how it works in the body. It is an open-label study, so both you and the doctors know what treatment is being given. The study is divided into two parts: finding the right dose in Part 1, and testing this dose on more people in Part 2. Participants must be at least 18 years old and have a specific type of cancer resistant to other treatments.

• The study involves taking the medicine by mouth.
• You might not be eligible if you have certain health conditions or are pregnant.
• The study checks for safety and does not guarantee a cure.